Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement.
P F
PF
Ferrucci
A
A
Vanazzi
G
G
Tesoriere
M
M
Ferrari
M
M
Bartolomei
P
P
Rocca
M
M
Cremonesi
G
G
Paganelli
G
G
Martinelli
D000328:Adult; D000911:Antibodies, Monoclonal / Q000134:cerebrospinal fluid* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D016499:Radioimmunotherapy; D033581:Stem Cell Transplantation; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; C422802:ibritumomab tiuxetan